Establishment Labs reports Q2 EPS (57c), consensus (56c)

Reports Q2 revenue $51.3M, consensus $51.1M. “Our US sales momentum has continued into the third quarter, allowing us to increase our worldwide and US guidance,” said Peter Caldini, Chief Executive Officer. “Outside the United States, we saw sequential growth in all regions. We have growth drivers for many years to come. Higher surgeon utilization and adding accounts in the United States will drive growth for the rest of this year and into next. Approval of additional sizes will accelerate both of these. Our minimally invasive portfolio is changing the narrative and attracting new patients to our category. Having our indication for breast reconstruction in the US will also be a considerable catalyst. The improved EBITDA and reduced cash loss in the second quarter reflect the increasing scale in the business and improving execution and cost efficiencies. We remain on track to achieve positive EBITDA in 2025 and become cash flow positive in 2026.”